Trial · NCT02688140
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
NCT02688140, Phase 3, Completed, Technische Universität Dresden
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia. Trials, record NCT02688140. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02688140
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
- NCT number
- NCT02688140
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 133 participants, actual
- Lead sponsor
- Technische Universität Dresden
- Conditions
- Acute Promyelocytic Leukemia
- Interventions
- Arsenic trioxide, Idarubicin, Cytarabine, Tretinoin, Mitoxantrone, Mercaptopurine, Methotrexate
- First posted
- 2016-02-23
- Last updated
- 2026-05-29
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Event-free survival | From date of randomization until the date of first documented event, assessed up to 66 months | events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS |
| Secondary | Rate of hematological complete remission | up to 60 days, from date of randomization until end of induction therapy | |
| Secondary | Rate of early death within 30 days after randomization | up to 30 days after randomization | |
| Secondary | Rate of overall survival (OS) | at 2 years | |
| Secondary | Rate of cumulative incidence of secondary MDS or AML | assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS | |
| Secondary | Rate of cumulative incidence of relapse (CIR) | at 2 years | |
| Secondary | Incidence of hematological and non-hematological toxicity | assessed up to 30 months after randomization | |
| Secondary | Rate of molecular remission after the last consolidation cycle | up to 256 days after randomization | |
| Secondary | Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study | assessed up to 30 months after randomization | |
| Secondary | Quality of Life at the end of induction therapy until the end of study | assessed up to 30 months after randomization |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40825164 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02688140
GET https://conductscience.org/api/trials/v1/NCT02688140/registered